WHO Adds First Molecular Diagnostic Test for Bundibugyo Ebola Virus to Emergency Use Listing

Key Facts

• On 2 July 2026, WHO added the first molecular diagnostic test specific for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL).
• The diagnostic test detects the virus by identifying its genetic material in blood samples, aiding rapid and accurate confirmation of infection.
• Bundibugyo virus is one of the species of the genus Ebolavirus causing Ebola disease in humans, first identified in Uganda in 2007.
• This virus is genetically distinct from the Zaire ebolavirus strain, which is the target of most existing licensed Ebola therapeutics and diagnostic platforms.
• As of 2 July 2026, the Democratic Republic of the Congo reported 1,406 laboratory-confirmed cases and 438 deaths related to the Bundibugyo virus outbreak, described as the largest recorded outbreak caused by this virus.
• On 17 May 2026, WHO declared the Bundibugyo Ebola outbreak a Public Health Emergency of International Concern (PHEIC), involving cases in DRC and Uganda.
• Laboratory testing capacity in affected DRC provinces increased from an estimated 200–400 tests per day at a few sites to over 2,000 tests per day across 10 laboratories.
• Existing diagnostic platforms and therapeutics effective for Zaire ebolavirus do not reliably detect or target Bundibugyo virus.
• The EUL procedure allows WHO to assess and list unlicensed medical products during emergencies to facilitate rapid access and informed procurement decisions by countries and UN agencies.

Background & Context

Bundibugyo virus belongs to the genus Ebolavirus and causes Ebola virus disease (EVD), a severe hemorrhagic fever. Discovered in Uganda in 2007, it differs genetically from the well-known Zaire ebolavirus strain. Unlike Zaire strain diagnostics and treatments, specific tools are required for Bundibugyo virus. The 2026 outbreak in DRC and Uganda led WHO to declare a PHEIC in May 2026, underscoring the urgency for accurate and timely diagnostics to identify cases, facilitate patient care, and control transmission.

Why This Matters for Exams / Exam Relevance

Understanding the WHO Emergency Use Listing illustrates the international response framework to emerging public health threats and the regulatory pathways for emergency medical products. The distinction among Ebola virus species, especially Bundibugyo and Zaire ebolaviruses, is critical due to differences in virus genetics, diagnostics, and therapeutics. Knowledge of outbreak management strategies, such as scaling laboratory testing and declaring PHEICs, also forms essential public health curriculum content.

Points to Remember

• Bundibugyo virus causes Ebola disease and is genetically distinct from Zaire ebolavirus; discovered in Uganda in 2007.
• First molecular diagnostic test for Bundibugyo virus was added to WHO's Emergency Use Listing on 2 July 2026.
• Largest recorded Bundibugyo Ebola outbreak occurred in 2026, primarily in the Democratic Republic of the Congo and Uganda.
• WHO declared the outbreak a Public Health Emergency of International Concern on 17 May 2026.
• Existing Ebola diagnostics and therapeutics mostly target Zaire strain and are ineffective against Bundibugyo virus.
• The emergency use listing helps expedite access to quality-assured diagnostics critical for outbreak control.
• Laboratory testing capacity in the affected regions was scaled up to over 2,000 tests daily across multiple labs.
• Rapid and accurate diagnosis is a cornerstone of clinical management and outbreak containment for Ebola disease.